Ceftaroline: Clinical Trials

16 trials of Ceftaroline, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 terminated, 3 unknown, 2 withdrawn. 16 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 416Completed 7, Terminated 3, Unknown 3, Withdrawn 2, Enrolling by invitation 1

Follow Ceftaroline: new trials by email Literature Review of Ceftaroline trials Research Report on Ceftaroline

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA - Staphylococcus Aureus Bacteremia
Phase 4Enrolling by invitationWest Virginia University3002025-09-152026-09-17
Comparing Oral Versus Parenteral Antimicrobial Therapy
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem - Endovascular Infection, Bone and Joint Infection
Phase 4TerminatedWest Virginia University942023-08-042025-08-26
Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline - Endocarditis
Phase 4TerminatedWest Virginia University52022-03-162026-05-05
Antibiotic Prophylaxis in Open Fractures
Ceftaroline - Open Fractures
Phase 4UnknownOlayemi Osiyemi MD502016-12-012016-10-28
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
Daptomycin, Vancomycin, Ceftaroline - Bacteremia
Phase 4CompletedSharp HealthCare402015-11-012018-02-01
The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection
Ceftaroline, Cefazolin / Vancomycin - Surgical Site Infection
Phase 4UnknownUniversity of Cincinnati5002015-01-012015-12-02
Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy
Ceftaroline in CRRT, Ceftaroline in IRRT - Infection During Renal Replacement Therapy
Phase 4UnknownMedical University of Vienna252013-12-012022-04-14
Ceftaroline in the Treatment of Bone and Joint Infections
Ceftaroline - Osteomyelitis, Joint Infections
Phase 4WithdrawnOrlando Health, Inc.2013-04-012014-08-07
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
Ceftaroline fosamil - Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Phase 4CompletedForest Laboratories562013-01-012014-07-31
Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia
Ceftaroline fosamil - Community-Acquired Bacterial Pneumonia (CABP)
Phase 4WithdrawnForest Laboratories2012-11-012013-02-11
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
Ceftaroline fosamil, Ceftriaxone plus vancomycin - Infections
Phase 4CompletedForest Laboratories492012-10-012016-02-01
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin - Infections, Pneumonia
Phase 4CompletedForest Laboratories402012-10-012015-11-02
Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia
Ceftaroline, Levofloxacin - Pneumonia, Bacterial, Community-acquired
Phase 4CompletedGary E. Stein, Pharm.D.122012-02-012016-04-12
Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA
Ceftaroline, Vancomycin - Skin Diseases, Infectious, Staphylococcal Skin Infections
Phase 4CompletedWayne State University1742012-02-012016-11-01
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
Vancomycin, Ceftaroline, Daptomycin - Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis
Phase 4TerminatedHenry Ford Health System1002011-10-012023-05-03
Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
Ceftaroline fosamil - Infections
Phase 4CompletedForest Laboratories532011-04-012014-05-14

Conditions studied

Infections (5)  ·  Bacteremia (3)  ·  Pneumonia (3)  ·  Endocarditis (2)  ·  Osteomyelitis (2)  ·  Arthritis, Infectious (1)  ·  Community-Acquired Pneumonia (1)  ·  Fractures, Open (1)  ·  Pneumonia, Bacterial (1)  ·  Skin Diseases, Infectious (1)  ·  Soft Tissue Infections (1)  ·  Staphylococcal Skin Infections (1)  ·  Surgical Wound Infection (1)

Sponsors

Forest Laboratories (5)  ·  West Virginia University (3)  ·  Gary E. Stein, Pharm.D. (1)  ·  Henry Ford Health System (1)  ·  Medical University of Vienna (1)  ·  Olayemi Osiyemi MD (1)  ·  Orlando Health, Inc. (1)  ·  Sharp HealthCare (1)  ·  University of Cincinnati (1)  ·  Wayne State University (1)

Countries

United States (14)  ·  Georgia (2)  ·  Ukraine (2)  ·  Argentina (1)  ·  Austria (1)  ·  Hungary (1)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)  ·  Spain (1)

Top investigators

Alan G Smulian, M.B.B.Ch. (1)  ·  Arif R Sawari, MD, MSc, MBA (1)  ·  Arif R. Sarwari, MD, MSc, MBA (1)  ·  DeAnn Cary, PhD (1)  ·  Gary E Stein, Pharm.D. (1)  ·  Jose Vazquez, M.D. (1)  ·  Joy J Juskowich, MD (1)  ·  Joy J. Juskowich, MD (1)  ·  Mark R. Wallace, MD (1)  ·  Michael Rybak, PharmD, MPH (1)  ·  Olayemi Osiyemi, MD (1)  ·  Vinay Badhwar, MD (1)

Results publications

PMID 30858203, PMID 30915685, PMID 41419216